Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PCVX
PCVX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PCVX News
Surge in Options Trading Volume for Marvell Technology
5d ago
NASDAQ.COM
Vera Therapeutics Appoints New Chief Legal Officer
6d ago
Newsfilter
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
Mar 21 2026
Yahoo Finance
Wall Street Analysts Adjust Ratings
Feb 26 2026
Benzinga
Vaxcyte Reports Q4 and Full-Year 2025 Financial Results and Business Update
Feb 25 2026
NASDAQ.COM
Vaxcyte Reports Q4 Losses and Cash Position
Feb 24 2026
seekingalpha
Vaxcyte Initiates Phase 3 Trial for VAX-31 Vaccine
Feb 12 2026
NASDAQ.COM
Vaxcyte Prices Public Offering at $550 Million
Jan 30 2026
Newsfilter
Vaxcyte Initiates Phase 3 Trials for VAX-31, Market Cap Around $7 Billion
Jan 23 2026
Benzinga
Vaxcyte Advances VAX-31 Vaccine with 95% Coverage for Adults
Jan 23 2026
NASDAQ.COM
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Jan 16 2026
Barron's
Vaxcyte CTO Sells 9,743 Shares Worth Approximately $454,891 Amidst Stock Decline
Jan 03 2026
NASDAQ.COM
Vaxcyte's CTO Sells 9,743 Shares Valued at Approximately $454,891
Jan 03 2026
Fool
This Pharmaceutical Stock Struggled Last Year, But One Analyst Believes It Could Surge 250%.
Dec 22 2025
Barron's
Mizuho's Lesser-Known Stock Choice for 2026: A Wall Street Favorite That Could See Its Value Triple
Dec 20 2025
CNBC
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Dec 11 2025
MarketWatch
Show More News
